MedTrace Logo

Xanthohumol and Viral Infections (XL)

NCT06286657 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-04-15

No results posted yet for this study

Summary

The aim of the present study is to determine if a regular oral supplementation of xanthohumol attenuate the severity of symptoms and duration of´viral infections.

Conditions

  • Infection Viral

Interventions

DIETARY_SUPPLEMENT

Xanthohumol

Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days

DIETARY_SUPPLEMENT

Placebo

Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days

Sponsors & Collaborators

  • University of Vienna

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2025-10-31
Completion
2025-12-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06286657 on ClinicalTrials.gov